Therapeutic drug monitoring of antifungal agents;Therapeutisches Drug Monitoring von Antimykotika

LaboratoriumsMedizin

Volumn 36, Issue 2, 2012, Pages 99-109

  Heinz, Werner J ^a   Klinker, Hartwig ^a  

^a UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

Author keywords

antifungal agents; azoles; drug monitoring; mycosis

Indexed keywords

ANTIFUNGAL AGENT; FLUCYTOSINE; NEW DRUG; PYRROLE DERIVATIVE;

ADVERSE OUTCOME; ARTICLE; CLINICAL PRACTICE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG MONITORING; HUMAN; MOULD; MYCOSIS; NONHUMAN; PRACTICE GUIDELINE; YEAST;

EID: 84860539694     PISSN: 03423026     EISSN: 14390477     Source Type: Journal    
DOI: 10.1515/labmed-2011-0012     Document Type: Article

References (81)

1. Ruhnke M, Rickerts V, Cornely OA, Buchheidt D, Glockner A, Heinz W, et al. Diagnosis and therapy of Candida infections: joint recommendations of the German Speaking Mycological Society and the Paul-Ehrlich-Society for Chemotherapy. Mycoses 2011;54:279-310.
2. Lin SJ, Schranz J, Teutsch SM. Aspergillosis case-fatality rate: systematic review of the literature. Clin Infect Dis 2001;32:358-66. (Pubitemid 32173620)
3. Bohme A, Ruhnke M, Buchheidt D, Cornely OA, Einsele H, Enzensberger R, et al. Treatment of invasive fungal infections in cancer patients-recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Ann Hematol 2009;88:97-110.
4. Freifeld AG, Bow EJ, Sepkowitz KA, Boeckh MJ, Ito JI, Mullen CA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of America. Clin Infect Dis 2011;52:e56-93.
5. Maertens J, Marchetti O, Herbrecht R, Cornely OA, Fluckiger U, Frere P, et al. European guidelines for antifungal management in leukemia and hematopoietic stem cell transplant recipients: summary of the ECIL 3-2009 update. Bone Marrow Transplant 2011;46:709-18.
6. Shen JX, Krishna G, Hayes RN. A sensitive liquid chromato-graphy and mass spectrometry method for the determination of posaconazole in human plasma. J Pharm Biomed Anal 2007;43:228-36. (Pubitemid 44856187)
7. Kahle K, Langmann P, Schirmer D, Lenker U, Keller D, Helle A, et al. Simultaneous determination of voriconazole and posaconazole concentrations in human plasma by high-performance liquid chromatography. Antimicrob Agents Chemother 2009;53:3140-2.
8. Chhun S, Rey E, Tran A, Lortholary O, Pons G, Jullien V. Simultaneous quantification of voriconazole and posaconazole in human plasma by high-performance liquid chromatography with ultra-violet detection. J Chromatogr B Analyt Technol Biomed Life Sci 2007;852:223-8. (Pubitemid 46839210)
9. Kim H, Kumari P, Laughlin M, Hilbert MJ, Indelicato SR, Lim J, et al. Use of high-performance liquid chromatographic and microbiological analyses for evaluating the presence or absence of active metabolites of the antifungal posaconazole in human plasma. J Chromatogr A 2003;987:243-8. (Pubitemid 36140101)
10. Muller C, Arndt M, Queckenberg C, Cornely OA, Theisohn M. HPLC analysis of the antifungal agent posaconazole in patients with haematological diseases. Mycoses 2006;49(Suppl 1):17-22. (Pubitemid 44370097)
11. Storzinger D, Swoboda S, Lichtenstern C, Muller C, Weigand MA, Hoppe-Tichy T. Development and validation of a high-performance liquid chromatography assay for posaconazole utilizing solid-phase extraction. Clin Chem Lab Med 2008;46: 1747-51.
12. Bruggemann RJ, Touw DJ, Aarnoutse RE, Verweij PE, Burger DM. International interlaboratory proficiency testing program for measurement of azole antifungal plasma concentrations. Antimicrob Agents Chemother 2009;53:303-5.
13. Alak A, Moy S, Bekersky I. A high-performance liquid chromatographic assay for the determination of amphotericin B serum concentrations after the administration of AmBisome, a liposomal amphotericin B formulation. Ther Drug Monit 1996;18:604-9. (Pubitemid 26330484)
14. Chavez-Eng CM, Schwartz M, Constanzer ML, Matuszewski BK. Determination of a cyclic hexapeptide, a novel antifungal agent, in human plasma by high-performance liquid chromatography with ion spray and turbo ion spray tandem mass spectrometric detection. J Chromatogr B Biomed Sci Appl 1999;721: 229-38. (Pubitemid 29142345)
15. Sutherland CA, Nicolau DP, Kuti JL. Development of an HPLC method for the determination of anidulafungin in human plasma and saline. J Chromatogr Sci 2011;49:397-400.
16. Uranishi H, Nakamura M, Nakamura H, Ikeda Y, Otsuka M, Kato Z, et al. Direct-injection HPLC method of measuring micafungin in human plasma using a novel hydrophobic/hydrophilic hybrid ODS column. J Chromatogr B Analyt Technol Biomed Life Sci 2011;879:1029-32.
17. Wong-Beringer A, Jacobs RA, Guglielmo BJ. Lipid formulations of amphotericin B: clinical efficacy and toxicities. Clin Infect Dis 1998;27:603-18. (Pubitemid 28422013)
18. Watanabe A, Matsumoto K, Igari H, Uesato M, Yoshida S, Nakamura Y, et al. Comparison between concentrations of amphotericin B in infected lung lesion and in uninfected lung tissue in a patient treated with liposomal amphotericin B (AmBisome). Int J Infect Dis 2010;14(Suppl 3):e220-3.
19. Walsh TJ, Goodman JL, Pappas P, Bekersky I, Buell DN, Roden M, et al. Safety, tolerance, and pharmacokinetics of high-dose liposomal amphotericin B (AmBisome) in patients infected with Aspergillus species and other filamentous fungi: maximum tolerated dose study. Antimicrob Agents Chemother 2001;45:3487-96. (Pubitemid 33107867)
20. Ellis M. New dosing strategies for liposomal amphotericin B in high-risk patients. Clin Microbiol Infect 2008;14(Suppl 4):55-64. (Pubitemid 351593917)
21. Bekersky I, Fielding RM, Dressler DE, Lee JW, Buell DN, Walsh TJ. Pharmacokinetics, excretion, and mass balance of liposomal amphotericin B (AmBisome) and amphotericin B deox-ycholate in humans. Antimicrob Agents Chemother 2002;46: 828-33. (Pubitemid 34157670)
22. Linden PK. Amphotericin B lipid complex for the treatment of invasive fungal infections. Expert Opin Pharmacother 2003;4:2099-110. (Pubitemid 37408121)
23. Mehta P, Vinks A, Filipovich A, Vaughn G, Fearing D, Sper C, et al. High-dose weekly AmBisome antifungal prophylaxis in pediatric patients undergoing hematopoietic stem cell transplantation: a pharmacokinetic study. Biol Blood Marrow Transplant 2006;12:235-40. (Pubitemid 43138018)
24. Wurthwein G, Young C, Lanvers-Kaminsky C, Hempel G, Trame MN, Schwerdtfeger R, et al. Population pharmacokinetics of liposomal amphotericin B and caspofungin in allogeneic hematopoietic stem cell recipients. Antimicrob Agents Chemother 2012;56:536-43.
25. Cordonnier C, Mohty M, Faucher C, Pautas C, Robin M, Vey N, et al. Safety of a weekly high dose of liposomal amphotericin B for prophylaxis of invasive fungal infection in immunocompro-mised patients: PROPHYSOME Study. Int J Antimicrob Agents 2008;31:135-41.
26. Groll AH, Walsh TJ. Caspofungin: pharmacology, safety and therapeutic potential in superficial and invasive fungal infections. Expert Opin Investig Drugs 2001;10:1545-58. (Pubitemid 32717334)
27. Marr KA, Hachem R, Papanicolaou G, Somani J, Arduino JM, Lipka CJ, et al. Retrospective study of the hepatic safety pro-file of patients concomitantly treated with caspofungin and cyclosporin A. Transpl Infect Dis 2004;6:110-6. (Pubitemid 40013050)
28. Sanz-Rodriguez C, Arranz R, Cisneros JM, Garcia-Sanchez PJ, Jurado M, Lopez J, et al. Absence of clinically relevant effect of caspofungin on cyclosporin pharmacokinetics. Swiss Med Wkly 2005;135:658-9. (Pubitemid 41811598)
29. Nguyen TH, Hoppe-Tichy T, Geiss HK, Rastall AC, Swoboda S, Schmidt J, et al. Factors influencing caspofungin plasma concentrations in patients of a surgical intensive care unit. J Antimicrob Chemother 2007;60:100-6. (Pubitemid 47073282)
30. Jarvis B, Figgitt DP, Scott LJ. Micafungin. Drugs 2004;64:969-82; discussion 83-4.
31. Keating GM, Jarvis B. Caspofungin. Drugs 2001;61:1121-9; discussion 30-1. (Pubitemid 32663869)
32. Cornely OA, Vehreschild JJ, Vehreschild MJ, Wurthwein G, Arenz D, Schwartz S, et al. Phase II dose escalation study of caspofungin for invasive aspergillosis. Antimicrob Agents Chemother 2011;55:5798-803.
33. Louie A, Deziel M, Liu W, Drusano MF, Gumbo T, Drusano GL. Pharmacodynamics of caspofungin in a murine model of systemic candidiasis: importance of persistence of caspofungin in tissues to understanding drug activity. Antimicrob Agents Chemother 2005;49:5058-68. (Pubitemid 41778921)
34. Nicasio AM, Tessier PR, Nicolau DP, Knauft RF, Russomanno J, Shore E, et al. Bronchopulmonary disposition of micafungin in healthy adult volunteers. Antimicrob Agents Chemother 2009;53:1218-20.
35. Pappas PG, Rotstein CM, Betts RF, Nucci M, Talwar D, De Waele JJ, et al. Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis. Clin Infect Dis 2007;45:883-93. (Pubitemid 47580382)
36. Betts RF, Nucci M, Talwar D, Gareca M, Queiroz-Telles F, Bedimo RJ, et al. A multicenter, double-blind trial of a high-dose caspofungin treatment regimen versus a standard caspofungin treatment regimen for adult patients with invasive candidiasis. Clin Infect Dis 2009;48:1676-84.
37. Migoya EM, Mistry GC, Stone JA, Comisar W, Sun P, Norcross A, et al. Safety and pharmacokinetics of higher doses of caspofungin in healthy adult participants. J Clin Pharmacol 2011;51:202-11.
38. Perfect JR, Dismukes WE, Dromer F, Goldman DL, Graybill JR, Hamill RJ, et al. Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the infectious diseases society of America. Clin Infect Dis 2010;50:291-322.
39. Pasqualotto AC, Howard SJ, Moore CB, Denning DW. Flucytosine therapeutic monitoring: 15 years experience from the UK. J Antimicrob Chemother 2007;59:791-3. (Pubitemid 47073421)
40. Andes D, van Ogtrop M. In vivo characterization of the pharmacodynamics of flucytosine in a neutropenic murine disseminated candidiasis model. Antimicrob Agents Chemother 2000;44:938-42. (Pubitemid 30165273)
41. Stamm AM, Diasio RB, Dismukes WE, Shadomy S, Cloud GA, Bowles CA, et al. Toxicity of amphotericin B plus flucytosine in 194 patients with cryptococcal meningitis. Am J Med 1987;83:236-42.
42. Francis P, Walsh TJ. Evolving role of flucytosine in immunocom-promised patients: new insights into safety, pharmacokinetics, and antifungal therapy. Clin Infect Dis 1992;15:1003-18.
43. Bennett JE, Dismukes WE, Duma RJ, Medoff G, Sande MA, Gallis H, et al. A comparison of amphotericin B alone and combined with flucytosine in the treatment of cryptoccal meningitis. N Engl J Med 1979;301:126-31. (Pubitemid 10225854)
44. Charlier C, Hart E, Lefort A, Ribaud P, Dromer F, Denning DW, et al. Fluconazole for the management of invasive candidiasis: where do we stand after 15 years? J Antimicrob Chemother 2006;57:384-410. (Pubitemid 43240191)
45. Pai MP, Turpin RS, Garey KW. Association of fluconazole area under the concentration-time curve/MIC and dose/MIC ratios with mortality in nonneutropenic patients with candidemia. Antimicrob Agents Chemother 2007;51:35-9. (Pubitemid 46047684)
46. Csajka C, Decosterd LA, Buclin T, Pagani JL, Fattinger K, Bille J, et al. Population pharmacokinetics of fluconazole given for secondary prevention of oropharyngeal candidiasis in HIV-positive patients. Eur J Clin Pharmacol 2001;57:723-7. (Pubitemid 34031265)
47. Smith J, Andes D. Therapeutic drug monitoring of antifungals: pharmacokinetic and pharmacodynamic considerations. Ther Drug Monit 2008;30:167-72. (Pubitemid 351521643)
48. Denning DW, Tucker RM, Hanson LH, Hamilton JR, Stevens DA. Itraconazole therapy for cryptococcal meningitis and cryptococcosis. Arch Intern Med 1989;149:2301-8. (Pubitemid 19258176)
49. Cartledge JD, Midgely J, Gazzard BG. Itraconazole solution: higher serum drug concentrations and better clinical response rates than the capsule formulation in acquired immunodeficiency syndrome patients with candidosis. J Clin Pathol 1997;50:477-80. (Pubitemid 27315993)
50. Tricot G, Joosten E, Boogaerts MA, Vande Pitte J, Cauwenbergh G. Ketoconazole vs. itraconazole for antifungal prophylaxis in patients with severe granulocytopenia: preliminary results of two nonrandomized studies. Rev Infect Dis 1987;9(Suppl 1):S94-9.
51. Glasmacher A, Hahn C, Molitor E, Marklein G, Sauerbruch T, Schmidt-Wolf IG. Itraconazole trough concentrations in antifungal prophylaxis with six different dosing regimens using hydroxypropyl-beta-cyclodextrin oral solution or coated-pellet capsules. Mycoses 1999;42:591-600. (Pubitemid 30053362)
52. Winston DJ, Busuttil RW. Randomized controlled trial of oral itraconazole solution versus intravenous/oral fluconazole for prevention of fungal infections in liver transplant recipients. Transplantation 2002;74:688-95.
53. Glasmacher A, Prentice A, Gorschluter M, Engelhart S, Hahn C, Djulbegovic B, et al. Itraconazole prevents invasive fungal infections in neutropenic patients treated for hematologic malignancies: evidence from a meta-analysis of 3, 597 patients. J Clin Oncol 2003;21:4615-26. (Pubitemid 46594036)
54. Lestner JM, Roberts SA, Moore CB, Howard SJ, Denning DW, Hope WW. Toxicodynamics of itraconazole: implications for therapeutic drug monitoring. Clin Infect Dis 2009;49:928-30.
55. Prentice AG, Glasmacher A. Making sense of itraconazole pharmacokinetics. J Antimicrob Chemother 2005;56(Suppl 1):i17-i22. (Pubitemid 41236086)
56. Gubbins PO, McConnell SA, Gurley BJ, Fincher TK, Franks AM, Williams DK, et al. Influence of grapefruit juice on the systemic availability of itraconazole oral solution in healthy adult volunteers. Pharmacotherapy 2004;24:460-7. (Pubitemid 38420532)
57. Walsh TJ, Anaissie EJ, Denning DW, Herbrecht R, Kontoyiannis DP, Marr KA, et al. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis 2008;46:327-60. (Pubitemid 351265310)
58. Troke PF, Hockey HP, Hope WW. Observational study of the clinical efficacy of voriconazole and its relationship to plasma concentrations in patients. Antimicrob Agents Chemother 2011;55:4782-8.
59. Miyakis S, van Hal SJ, Ray J, Marriott D. Voriconazole concentrations and outcome of invasive fungal infections. Clin Microbiol Infect 2010;16:927-33.
60. Denning DW, Ribaud P, Milpied N, Caillot D, Herbrecht R, Thiel E, et al. Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. Clin Infect Dis 2002;34:563-71. (Pubitemid 34165316)
61. Trifilio S, Singhal S, Williams S, Frankfurt O, Gordon L, Evens A, et al. Breakthrough fungal infections after allogeneic hematopoietic stem cell transplantation in patients on prophylactic voriconazole. Bone Marrow Transplant 2007;40:451-6. (Pubitemid 47288224)
62. Pascual A, Calandra T, Bolay S, Buclin T, Bille J, Marchetti O. Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. Clin Infect Dis 2008;46:201-11. (Pubitemid 351269158)
63. Tan K, Brayshaw N, Tomaszewski K, Troke P, Wood N. Investigation of the potential relationships between plasma voriconazole concentrations and visual adverse events or liver function test abnormalities. J Clin Pharmacol 2006;46:235-43. (Pubitemid 43146453)
64. Trifilio S, Pennick G, Pi J, Zook J, Golf M, Kaniecki K, et al. Monitoring plasma voriconazole levels may be necessary to avoid subtherapeutic levels in hematopoietic stem cell transplant recipients. Cancer 2007;109:1532-5. (Pubitemid 46595688)
65. Driscoll TA, Yu LC, Frangoul H, Krance RA, Nemecek E, Blumer J, et al. Comparison of pharmacokinetics and safety of voriconazole intravenous-to-oral switch in immunocompromised children and healthy adults. Antimicrob Agents Chemother 2011;55:5770-9.
66. Pasqualotto AC, Xavier MO, Andreolla HF, Linden R. Voriconazole therapeutic drug monitoring: focus on safety. Expert Opin Drug Saf 2010;9:125-37.
67. Rengelshausen J, Banfield M, Riedel KD, Burhenne J, Weiss J, Thomsen T, et al. Opposite effects of short-term and long-term St John ' s wort intake on voriconazole pharmacokinetics. Clin Pharmacol Ther 2005;78:25-33. (Pubitemid 40956928)
68. Wang G, Lei HP, Li Z, Tan ZR, Guo D, Fan L, et al. The CYP2C19 ultra-rapid metabolizer genotype influences the pharmacokinetics of voriconazole in healthy male volunteers. Eur J Clin Pharmacol 2009;65:281-5.
69. Purkins L, Wood N, Greenhalgh K, Allen MJ, Oliver SD. Voriconazole, a novel wide-spectrum triazole: oral pharmacokinetics and safety. Br J Clin Pharmacol 2003;56(Suppl 1):10-6. (Pubitemid 37491728)
70. Walsh TJ, Raad I, Patterson TF, Chandrasekar P, Donowitz GR, Graybill R, et al. Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: an externally controlled trial. Clin Infect Dis 2007;44:2-12. (Pubitemid 44968977)
71. Jang SH, Colangelo PM, Gobburu JV. Exposure-response of posaconazole used for prophylaxis against invasive fungal infections: evaluating the need to adjust doses based on drug concentrations in plasma. Clin Pharmacol Ther 2010;88:115-9.
72. Ullmann AJ, Cornely OA, Burchardt A, Hachem R, Kontoyi-annis DP, Topelt K, et al. Pharmacokinetics, safety, and efficacy of posaconazole in patients with persistent febrile neutropenia or refractory invasive fungal infection. Antimicrob Agents Chemother 2006;50:658-66. (Pubitemid 43190980)
73. Krishna G, Moton A, Ma L, Medlock MM, McLeod J. Pharmacokinetics and absorption of posaconazole oral suspension under various gastric conditions in healthy volunteers. Antimicrob Agents Chemother 2009;53:958-66.
74. Ezzet F, Wexler D, Courtney R, Krishna G, Lim J, Laughlin M. Oral bioavailability of posaconazole in fasted healthy subjects: comparison between three regimens and basis for clinical dosage recommendations. Clin Pharmacokinet 2005;44:211-20. (Pubitemid 40188942)
75. Krishna G, Ma L, Vickery D, Yu X, Wu I, Power E, et al. Effect of varying amounts of a liquid nutritional supplement on the pharmacokinetics of posaconazole in healthy volunteers. Antimicrob Agents Chemother 2009;53:4749-52.
76. Sansone-Parsons A, Krishna G, Calzetta A, Wexler D, Kantesaria B, Rosenberg MA, et al. Effect of a nutritional supplement on posaconazole pharmacokinetics following oral administration to healthy volunteers. Antimicrob Agents Chemother 2006;50:1881-3.
77. Courtney R, Radwanski E, Lim J, Laughlin M. Pharmacokinetics of posaconazole coadministered with antacid in fasting or nonfasting healthy men. Antimicrob Agents Chemother 2004;48: 804-8. (Pubitemid 38280328)
78. Gubbins PO, Krishna G, Sansone-Parsons A, Penzak SR, Dong L, Martinho M, et al. Pharmacokinetics and safety of oral posaconazole in neutropenic stem cell transplant recipients. Antimicrob Agents Chemother 2006;50:1993-9. (Pubitemid 43807517)
79. Krishna G, Martinho M, Chandrasekar P, Ullmann AJ, Patino H. Pharmacokinetics of oral posaconazole in allogeneic hematopoietic stem cell transplant recipients with graft-versus-host disease. Pharmacotherapy 2007;27:1627-36. (Pubitemid 350234311)
80. Krishna G, Parsons A, Kantesaria B, Mant T. Evaluation of the pharmacokinetics of posaconazole and rifabutin following co-administration to healthy men. Curr Med Res Opin 2007;23:545-52. (Pubitemid 46456902)
81. Heinz WJ, Zirkel J, Kuhn A, Schirmer D, Lenker U, Keller D, et al. Relevance of timing for determination of posaconazole plasma concentrations. Antimicrob Agents Chemother 2011;55:3621-3.